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LETTER TO THE EDITOR
Continued Exploration
of Bevacizumab in Breast
Cancer
TO THE EDITORS:
We appreciate the opportunity to discuss the need for
continued exploration of bevacizumab in breast cancer. As
aptly noted by Drs. Ziogas and Roukos, the routine use of
bevacizumab should be discouraged in the adjuvant or
neoadjuvant setting in breast cancer; however, carefully
designed research studies should be encouraged to further
understand the indications for the optimal use of the anti-
angiogenic agents. In our published paper, we reported the
response of 16 HER-2-negative patients who received
bevacizumab with chemotherapy and compared the results
with 20 patients who did not receive bevacizumab.
Although the main focus of that work was the evaluation of
the imaging ﬁndings, the pathologic response between
these two groups was also reported.
The perceived lack of beneﬁt seen with use of bev-
acizumab is the result of many reasons, in addition to the
ones discussed by Drs. Ziogas and Roukos. In fact, the
reported patients in this study were a subset of a larger
number of patients treated at Chao Family Comprehensive
Cancer Center since 2003 (listed in http://clinicaltrials.gov).
The pathologic complete response (pCR) rate was high
despite inclusion of patients with inﬂammatory and meta-
static breast cancer, which might be attributed to application
of the following chemotherapy paradigms. First, we used
optimal scheduling of doxorubicin and cyclophosphamide
as induction therapy. Second, if a 50% reduction in the
tumor size was not attained after two cycles of doxorubicin
and cyclophosphamide, patients were switched to the sec-
ond-line regimen earlier. Third, because weekly paclitaxel
has an antiangiogenic effect, weekly low-dose paclitaxel is
considered the best way of administration, and it has been
found to have better efﬁcacy than once-every-3-weeks
paclitaxel scheduling.
1–5 Fourth, we used carboplatin with
weekly paclitaxel, which may speciﬁcally be important in
triple-negative breast cancer.
4
Inourarticle,weonlyanalyzedthesubsetofpatientswho
had completed magnetic resonance imaging (MRI) study.
Although the response in 16 patients (17 lesions) who
receivedbevacizumabwasslightlyinferior(5of17,29%)to
patients who did not receive bevacizumab (8 of 20, 40%), as
a result of the small subject number and nonrandomized
studydesign,thisresultdidnotprovidesufﬁcientsupporting
evidence to discourage the use of bevacizumab, and more
research is deﬁnitely needed. Importantly, HER-2-negative
breast cancer comprises heterogeneous subsets of breast
cancer that include luminal A, luminal B, triple-negative
nonbasal, triple-negative basal, and BRCA-associated breast
cancers, and all these factors may affect the reported pCR
rate.
WealsoagreewiththeotherlimitationsdescribedbyDrs.
Ziogas and Roukos. We are following all patients enrolled
onto our previous and current treatment studies to obtain the
long-term disease-free and overall survival data. Regarding
the predicted power of pCR, this issue is an important
research topic in the ﬁeld of oncology, and more data should
be forthcoming. As the association between residual disease
burden and patient’s prognosis becomes better established
and more widely accepted, dichotomizing patients into pCR
versus non-pCR should not be the only way to predict
prognosis.
6 As we showed in our article, MRI is not sensi-
tive to detect minimal residual disease presenting as
scattered cells or cell clusters. If it is further proven that
patients with minimal residual disease (small residual can-
cer burden) have comparable prognosis as those achieving
pCR, the MRI ﬁndings may play an important role in
management of these patients, despite this modality’s lim-
ited sensitivity in detecting such residual diseases.
Further exploration of the indication for use of bev-
acizumab is a laudable goal, and the Southwest Oncology
Group and Eastern Cooperative Oncology Group have
proposed large, randomized neoadjuvant trials that will test
some of the above-discussed paradigms, which include
dose-dense doxorubicin and cyclophosphamide sequenced
to metronomic (weekly) paclitaxel, with or without car-
boplatin and with or without bevacizumab. Therefore,
although we strongly agree with Drs. Ziogas and Roukos
that caution should be used in the routine use of bev-
acizumab in treatment protocols, we think that more
research studies that use appropriately designed protocols
approved by an internal review board, with patient’s
written informed consent, should be encouraged. Further-
more, we think that imaging can play an important role,
particularly in the neoadjuvant setting, and indeed, incor-
porating imaging into clinical cancer treatment trials is the
current trend. The role of imaging in guiding adjustment of
the optimal treatment protocol, as well as in planning of the
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should be investigated. The traditional biomarkers used for
management of breast cancer are molecular biomarkers.
The concept of using imaging ﬁndings as biomarkers is
evolving, and it is particularly suitable for management of
patients receiving neoadjuvant chemotherapy. Last, as
discussed by Drs. Ziogas and Roukos, there is a great need
for a better understanding of the molecular mechanisms
and genotype-phenotype relationships so that personalized
decisions about the use bevacizumab or other targeted
agents may be made.
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